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Background: In Luxembourg, a national Human Papillomavirus (HPV) vaccination programme was intro-
duced in 2008, targeting 12–17 year old girls offering a choice of bivalent or quadrivalent vaccine free of
charge. In 2015, the programme was changed offering the bivalent vaccine only to 11–13 year old girls.
The aim of this study was to evaluate the HPV vaccination coverage, to assess the impact of age target
changes and compare vaccination coverage to other European countries.
Methods: Anonymous HPV vaccination records consisting of individual vaccine doses obtained free of
charge in pharmacies between 2008 and 2016 were extracted from the Luxembourgish Social Security
database. Additional aggregate tables by nationality and municipality were analysed.
Results: Of the target cohort of 39,610 girls born between 1991 and 2003 residing in Luxembourg, 24,550
(62.0%) subjects obtained at least one dose, 22,082 (55.7%) obtained at least two doses, and 17,197
(43.4%) obtained three doses of HPV vaccine. The mean age at first dose was 13.7 years during 2008–
14 and 12.7 years in 2016 after the age target change. Coverage varied significantly by nationality (p <
0.0001): Portuguese (80%), former Yugoslavs (74%), Luxembourgish (54%), Belgian (52%), German
(47%), French (39%) and other nationalities (51%). Coverage varied also by geographical region, with lower
rates (<50%) noted in some Northern and Central areas of Luxembourg (range: 38% to 78%).
Conclusion: Overall HPV vaccination coverage in Luxembourg is moderate and varied by nationality and
region. The policy changes in 2015 did not have a substantial impact except lowering age at initiating
vaccination. Options to improve coverage deserve further investigation.
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The recognition that cervical cancer is etiologically linked with
persistent human papillomavirus (HPV) infection, [1,2] has led to
the development of various cervical cancer preventive pro-
grammes, including screening and vaccination [3]. In 2006, the first
HPV vaccine (Gardasil) was approved in the United States and the
European Union [4]. This quadrivalent vaccine targets genotypes 6,
11, 16 and 18. Genotypes 16 and 18 account for approximately 70%
of all cervical cancers, whereas genotypes 6 and 11 are the main
cause of genital warts [5–7]. In 2007, a bivalent HPV vaccine (Cer-
varix) was introduced to the market for the primary prevention of
genotypes 16 and 18. Since 2015, a nonavalent vaccine (Gardasil 9)
has become available in Europe targeting nine HPV genotypes (6,11, 16, 18, 31, 33, 45, 52, 58) [8]. By 31 March 2017, globally 71
countries have introduced national HPV vaccination programmes
including 26 countries in Europe [9]. By the end of 2014, 47 million
female subjects received HPV vaccines worldwide [10]. Recent
studies show a significant reduction of vaccine-associated geno-
types and protection from cervical lesions in vaccinated girls
[11–14]. Several countries reported a decrease in incidence of gen-
ital warts following the introduction of national HPV vaccination
programmes [15–17]. Moreover, the significant reduction of geno-
types 31, 33, and 45 not contained in vaccines suggests a degree of
cross-protection [12,18–20]. HPV vaccination has the potential to
prevent cervical cancer and related deaths worldwide [21].
In Luxembourg, the national HPV vaccination programme
started in March 2008 targeting 12–17 years old girls [22]. The pro-
gramme aimed to deliver three doses, ideally, before the onset of
sexual activity. When girls were 12 years old, they automatically
received an information letter from the National Health Insurance
and a brochure advising them to get vaccinated by their physician
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invitation letter and information brochure were provided in four
languages (Luxembourgish, German, French and Portuguese). Vac-
cines were typically administered as three intramuscular injections
over 6 months. The parents then collected the prescribed vaccine
doses from the pharmacy free of charge.
Following the updated 2014 WHO/EMA recommendation [23],
during the spring of 2015, the national vaccination policy was
changed limiting vaccination to girls aged 11–13 years with two
doses of bivalent vaccine over a 6 month interval. Girls aged 14–
17 years were still eligible to receive three doses of bivalent or
quadrivalent vaccine free of charge until the end of 2015.
The main purpose of this study was to evaluate the HPV vacci-
nation coverage in Luxembourg based on the analysis of National
Health Insurance records and compare it to the situation of coun-
tries in Europe with a similar health system.Fig. 1. HPV vaccination coverage per birth cohort.2. Materials and methods
2.1. Study population
The study was performed using the Luxembourgish Social Secu-
rity database, covering approximately 95% of the resident popula-
tion, the remaining fraction consisting mainly of European Union
institutions employees and their family members, which have their
own social security system. The information contained in the data-
base consists of patient characteristics, medical consultations,
interventions, prescriptions, laboratory tests and hospital dis-
charge data.
2.2. Data extraction and pseudonymisation
HPV vaccination records consisting of individual vaccine doses
obtained in pharmacies between 2008 and 2016 were requested
from the Social Security Inspection (http://www.mss.public.lu/ac-
teurs/igss/index.html) who have direct access to the database.
For data protection purposes, the Social Security Inspection chan-
ged personally identifiable social security numbers to pseudony-
mised identifiers for the study investigators so that no further
linkage to other health information was possible. The data set in
comma separated text format was transferred from the Social
Security Inspection to the study team by secure file transfer.
2.3. Characteristics of the dataset
The data set analysed in this study consisted of pseudonymised
personal identifiers, age at first vaccine dose acquisition, interval in
days between first, second and third dose, year of birth, calendar
year of obtaining the first, second and third dose, vaccine type,
medical speciality of the prescribing physician and total number
of doses obtained. For reasons of data protection only aggregate
tables by nationality and municipality could be obtained. National-
ity here refers to the nationality information recorded in the
national registry of physical persons at the time of data extraction.
In Luxembourg, nationality concept refers to citizenship. Addition-
ally, we received the following socioeconomic data aggregated at
commune level from the public statistics portal (http://www.
statistiques.public.lu/): average monthly income, unemployment
rate and frequency distribution of nationalities.
2.4. Statistics
Statistical analysis was performed in Stata 14.0 (StataCorp,
USA). We used Pearson’s correlation coefficient to assess the asso-
ciation between continuous variables. For the coverage calcula-tions girls born after 2004 year were excluded from the analysis,
since they had potentially not yet completed the full vaccination
schedule.
2.5. Ethics and data protection
The study was approved by the National Research Ethics Com-
mittee (CNER 201501/02) and the National Data Protection Com-
mission (CNPD 288/2016).
3. Results
At the end of 2016, 39,610 females born between 1991 and
2003 years were resident in Luxembourg according to the Social
Security database.
3.1. Vaccination coverage
Of that cohort 24,550 (62.0%) obtained at least one dose of HPV
vaccine, 22,082 (55.7%) obtained at least two doses, and 17,197
(43.4%) obtained three doses. 70.0% of girls initiating vaccination
completed a full schedule with three doses and 89.9% completed
a partial schedule with two doses. The lowest vaccination coverage
with at least one dose was observed in girls born in 1991, signifi-
cantly increasing in the following birth cohorts. The highest vacci-
nation coverage was noted for the cohort born in 1998, with at
least one, two and three dose coverages of 70.1%, 64.5% and
58.1%, respectively (Fig. 1).
3.2. Vaccine uptake over time
The total number of obtained vaccines per year varied substan-
tially over time. It was highest in the first year after vaccine intro-
duction, then stabilized until the policy changes in 2015 produced
another substantial increase (Fig. 2a). Approximately half of the
women born between 1991 and 1996 obtained their first dose in
2008 (Fig. 2b). The high vaccination uptake during the first year
was due to larger number of age groups eligible for the first time
(Fig. 2b). Despite the reduced target age range in 2016, the total
number of girls initiating vaccination was similar to 2014 (Fig. 2).
3.3. Vaccination coverage by region and nationality
Coverage varied geographically ranging from 38.4% to 78.6%,
and was lower in the North and Centre of Luxembourg. Communes
with the highest coverage are located in the Eastern and South-
western parts of the country (Fig. 3). Coverage was found to be
significantly associated with nationality (p < 0.0001), highest for
Portuguese (80%) or former Yugoslavs (74%), intermediate in
Fig. 2. a. Number of girls vaccinated per year and age. b. Proportion of obtained
vaccines (at least one dose) per birth cohort and year of vaccination.
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and lowest among the German (47%) or French (39%) residents
(Fig. 4).
3.4. Vaccination following policy change and vaccine distribution
The mean age at first dose was 13.7 years during 2008–14 and
12.7 years in 2016 after the age target change. During 2008–2014,
59.4% and 40.6% of vaccinated women obtained quadrivalent and
bivalent vaccine, respectively. During 2015–2016, 7.7% of vacci-
nated women obtained quadrivalent vaccine and 92.3% obtained
bivalent vaccine. The second and third doses were obtained after
90 (range: 0–1943) and 154 (range: 0–2076) days on average,
respectively. The total number of obtained vaccine doses during
2008–2016 was 63,829 consisting of 53.5% (34,139) quadrivalent
and 46.5% (29,690) bivalent vaccine doses.
3.5. Speciality of vaccine prescribers
During 2008–2014, 54.2% of doses were prescribed by general
practitioners, 30.5% by pediatricians and 14.5% by gynecologists.
During 2015–2016, 47.7%, 44.2% and 6.5% of vaccine doses were
prescribed by general practitioners, pediatricians and gynecolo-
gists, respectively. The mean age of girls vaccinated by general
practitioners was 13.9 years, 12.9 years for girls vaccinated by
pediatricians and 14.6 years for girls vaccinated by gynecologists
(Fig. 5). Fig. 5b shows that role of pediatricians in prescribing
HPV vaccine increased considerably for recent birth cohorts.
3.6. Vaccination coverage and socioeconomic status
The vaccination rate was not correlated with population den-
sity, average monthly income, unemployment rate or proportionof foreigners. A borderline correlation result was observed between
vaccination and proportion of French residents in a commune (p =
0.04, data not shown).4. Discussion
In this study, we assessed HPV vaccination coverage rates in
Luxembourg for the girls born between 1991 and 2003 years based
on the national health insurance data. Highest coverage and high-
est completion rate was observed in girls born in 1998, with at
least one, two and three dose coverages of 70.1%, 64.5% and
58.1%, respectively. Overall, vaccination coverage of at least one
dose was 62.0%, at least two doses was 55.7%, and three doses
was 43.4%. Coverage varied significantly by nationality and geo-
graphical region.
In Luxembourg, all childhood vaccines are administrated by pri-
vate and hospital physicians. The coverage of HPV vaccination is
relatively low compared to other vaccinations: immunisation cov-
erage for other childhood vaccines is approximately 95% [24]. One
of the reasons behind the difference in vaccination rates could be
physicians’ hesitancy to recommend HPV vaccine. Physician’s hesi-
tancy to vaccinate has already been known in the past to have
caused localised outbreaks of measles in the northern Luxembourg
[25]. We also observed lower HPV vaccination rates in some north-
ern parts of the country. Introducing HPV vaccination at school
level would represent a major challenge, as there is currently no
public infrastructure or personnel for vaccine administration.
HPV vaccination coverage with at least one dose appears to be
higher in Luxembourg than in other European countries without
school-based vaccination programmes. In neighbouring Germany
and France, one dose coverage is lower than 50% [26–28]. However,
in England and Scotland, where school-based delivery strategy is
used, coverage of one dose is 91% and 94% and coverage of three
doses is 86% and 81%, respectively [29]. In the Flanders region of
Belgium where school-based system coexists with opportunistic
vaccination by health centres, one dose coverage reached 90%
[30]. Denmark achieved a high vaccination coverage through gen-
eral practitioners, but coverage decreased significantly lately due
to vaccine hesitancy [31,32]. Several studies suggest that coverage
in a school-based delivery system is higher than in non-school-
based system [30,33–35]. Switching to school-based vaccination
in Canada led to a significant increase of coverage [36].
In Luxembourg, schedule completion rates for two doses was
90% and for three doses 70%, partly influenced by the change in
vaccination programme in 2015 offering only two doses (cf. girls
born in 2002 and 2003 in Fig. 1). In France only 49% of girls who
initiated vaccination completed the three-dose schedule [28]. In
Germany and Belgium approximately 80% of girls completed the
full schedule [27,37]. High completion rates were observed in Den-
mark reaching 92% [31]. Some recent studies suggest that one or
two doses schedules provide similar levels of protection than three
dose schedules [38].
Our study suggests HPV vaccination in Luxembourg was associ-
ated with nationality and regional factors. In particular, HPV vacci-
nation uptake was significantly lower in German and French
residents and higher in Portuguese and former Yugoslav residents,
which somewhat similar to vaccination coverage for other child-
hood vaccines [24]. This mirrors to a large extent vaccination
acceptance in these respective countries – lower than 50% in
France and Germany and higher than 80% in Portugal [10,26–28].
From former Yugoslav countries, coverage estimates are only avail-
able from Slovenia (70–74%) [39]. Many studies have shown eth-
nicity to be an import determinant of vaccination acceptance
[31,40]. Interestingly, in the Netherlands HPV vaccination uptake
is significantly lower in immigrants [41]. Similarly in France, lower
Fig. 3. HPV vaccine coverage (at least one dose) by geographic region.
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percentage of foreign population [28]. Sociodemographic inequali-
ties in HPV vaccination coverage were observed in countries with
low coverage or in countries without school-based programmes[30,36]. In Luxembourg, vaccination did not appear to be correlated
with average income, unemployment rate or distribution of foreign
nationalities at the geographical level of communes, although a
borderline correlation was observed with the proportion of French
Fig. 4. HPV vaccine coverage (at least one dose) by nationality.
Fig. 5. a. Number of girls vaccinated (at least one dose) by speciality of the
prescribing physician and age. b. Proportion of prescriber’s speciality per birth
cohort (at least one dose). Abbreviations: GP, general practitioner; PD, pediatrician;
GYN, gynecologists.
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tion in Luxembourg.
Since 2009–2010, the number of vaccine doses used in Luxem-
bourg decreased yielding a stabilisation of the vaccine coverage up
to cohort 1998 and decreasing in the following cohorts. It is
expected that birth cohorts 2004–2005 will have a higher coverage
than birth cohort 2003, considering that girls of 11–13 years are
better vaccinated in 2015–16 than the years before. However, the
birth cohort coverage will not increase, since girls older than 13
years no longer have the opportunity to get vaccinated after
2016. The lack of catch up vaccination could be problematic, since
Luxembourg has a high immigration rate (more than 100,000
migrants arriving in last five years). Incoming teenage interna-
tional protection seekers do not currently have an opportunity to
receive HPV vaccine.An interesting impact of the policy change is that vaccine pre-
scriber specialty is changing towards more pediatricians and GPs
and less gynecologists. This may suggest that it is easier for parents
to vaccinate girls when they are pre-teen visiting GPs or pediatri-
cians, rather than teenagers visiting gynecologists who are less
involved in administering vaccines in general. An advantage of a
shift of HPV vaccination towards younger groups is that the pro-
portion not yet exposed to HPV infection becomes higher. In addi-
tion, higher antibody titers were observed in younger girls aged 9–
14 years compared to older girls [28]. Therefore, these younger
cohorts will be more protected against HPV-related disease than
those who were vaccinated at age 16–18 in the first years of the
programme.
To our knowledge, this is the first study assessing HPV vaccina-
tion coverage in Luxembourg. To be able to monitor the impact of
HPV vaccination in the future it will be crucial to link HPV vaccina-
tion records with cervical cancer screening and cancer registry data
[42], completed with targeted HPV genotyping of samples [14].
Estimation of the impact of HPV vaccination in Luxembourg is
the aim of the ongoing Papillux research project, results of which
will be published shortly.
Ways to improve coverage include simplifying the logistics of
vaccine prescription and acquisition: currently parents who want
to vaccinate their girls need first to visit a prescribing doctor, obtain
the vaccine at the pharmacy and then return to the physician for
vaccine administration. It would be more efficient if doctors would
be able to keep a stock of vaccines from a central pharmacy as for
other childhood vaccines. Moreover, since physicians are very influ-
ential in the parents’ decision making process, it is important to
develop strategies addressing doctor’s hesitancy, targeting both
pediatricians and GPs. Educational activities targeting physicians
and specific population groups with lower vaccination coverage
could, for example, help to increase uptake. Additionally, it would
be feasible to provide catch up vaccination of international protec-
tion seekers who are above the narrow vaccination target age group
as part of their routine medical check up after registration.
Nevertheless, HPV vaccination coverage in Luxembourg
remains moderate and while challenging, increasing coverage for
residents and migrants of all nationalities and in all regions should
be an important public health priority.
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